This paper provides a summary of a roundtable discussion with senior biotech executives and Heads of Europe that took place in Zug, Switzerland on September 22, 2022.
Establishing an effective and inclusive governance model represents a key challenge for US-based biotech companies when interacting with their European business organizations. The roundtable members chose this topic because they viewed it as a key strategic issue that is highly relevant to the success of any US-based company planning to operate in Europe.
To better understand the proper purpose of US/EU governance and to identify the key issues surrounding it, Blue Matter conducted a short survey with a number of European business leaders of leading biotech/pharma companies. Once the key issues were identified, we worked with our co-authors to better understand the root causes of the issues and their direct implications. We also formulated some high-level recommendations to address those issues. At the roundtable meeting, we pressure-tested the above and conducted a “deep dive” into the recommendations to explore them further.
This paper consolidates the insights gathered from the survey and discussions
